Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04760652). This is a study registration, not published results. Lead sponsor: Yale University. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 93 participants (ACTUAL). Conditions: Depression and Suicide. Interventions: BEHAVIORAL: Cognitive Behavioral Therapy CBT; OTHER: TAU. Primary outcome measures: To Determine the Feasibility of Performing a Larger Study With Similar Design by Measuring of Recruitment Rates. , Recruitment rates will be assessed at 18 months.; To Determine the Feasibility of Performing a Larger Study With Similar Design by Measuring Attrition. , Attrition will be assessed at 18 months.; Reasons for Discontinuation , Discontinuation will be assessed at 18 months.; To Determine the Safety of Performing a Larger Study With Similar Design. , Safety will be assessed at 18 months.; Evaluate the Appropriateness of the Proposed Tests of Cognitive Control Measures in Exploring the Mechanisms of Change. , 6 months. Brief summary: This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI). Subjects will be randomized (1:1) to receive CBT (computer-assisted) or TAU alone following esketamine.